Literature DB >> 11825916

Cryoglobulins.

C Ferri1, A L Zignego, S A Pileri.   

Abstract

Serum cryoglobulins are found in a wide spectrum of disorders but are often transient and without clinical implications. Monoclonal cryoglobulins are usually associated with haematological disorders, whereas mixed cryoglobulins are found in many infectious and systemic disorders. So called essential mixed cryoglobulinaemia shows a striking association with hepatitis C virus (HCV) infection (> 90%). It is a systemic vasculitis (leucocytoclastic vasculitis) with cutaneous and multiple visceral organ involvement. Chronic HCV infection can lead to a constellation of autoimmune and neoplastic disorders. In this review, the aetiology, diagnosis, disease heterogeneity, and treatment of cryoglobulinaemia are discussed.

Entities:  

Mesh:

Year:  2002        PMID: 11825916      PMCID: PMC1769573          DOI: 10.1136/jcp.55.1.4

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  91 in total

1.  Hepatitis C virus in patients with cryoglobulinemia type II.

Authors:  M Pascual; L Perrin; E Giostra; J A Schifferli
Journal:  J Infect Dis       Date:  1990-08       Impact factor: 5.226

2.  Hepatitis C virus infection in patients with B-cell non-Hodgkin lymphoma.

Authors:  E Zuckerman; T Zuckerman; A M Levine; D Douer; K Gutekunst; M Mizokami; D G Qian; M Velankar; B N Nathwani; T L Fong
Journal:  Ann Intern Med       Date:  1997-09-15       Impact factor: 25.391

3.  Cryoglobulins are not essential.

Authors:  M Trendelenburg; J A Schifferli
Journal:  Ann Rheum Dis       Date:  1998-01       Impact factor: 19.103

4.  Exacerbation of peripheral neuropathy during alpha-interferon therapy in a patient with mixed cryoglobulinemia and hepatitis B virus infection.

Authors:  L La Civita; A L Zignego; F Lombardini; M Monti; G Longombardo; G Pasero; C Ferri
Journal:  J Rheumatol       Date:  1996-09       Impact factor: 4.666

5.  Treatment of the renal involvement in mixed cryoglobulinemia with prolonged plasma exchange.

Authors:  C Ferri; L Moriconi; G Gremignai; P Migliorini; G Paleologo; P V Fosella; S Bombardieri
Journal:  Nephron       Date:  1986       Impact factor: 2.847

6.  Hepatic lymphoid aggregates in chronic hepatitis C and mixed cryoglobulinemia.

Authors:  A Monteverde; M Ballarè; S Pileri
Journal:  Springer Semin Immunopathol       Date:  1997

7.  Pre-malignant and malignant lymphoproliferations in an HCV-infected type II mixed cryoglobulinemic patient are sequential phases of an antigen-driven pathological process.

Authors:  V De Re; S De Vita; A Marzotto; A Gloghini; B Pivetta; D Gasparotto; R Cannizzaro; A Carbone; M Boiocchi
Journal:  Int J Cancer       Date:  2000-07-15       Impact factor: 7.396

8.  Hepatitis C virus and porphyria cutanea tarda: evidence of a strong association.

Authors:  S Fargion; A Piperno; M D Cappellini; M Sampietro; A L Fracanzani; R Romano; R Caldarelli; R Marcelli; L Vecchi; G Fiorelli
Journal:  Hepatology       Date:  1992-12       Impact factor: 17.425

9.  Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.

Authors:  J G McHutchison; S C Gordon; E R Schiff; M L Shiffman; W M Lee; V K Rustgi; Z D Goodman; M H Ling; S Cort; J K Albrecht
Journal:  N Engl J Med       Date:  1998-11-19       Impact factor: 91.245

10.  Anti-DNA antibodies from autoimmune mice arise by clonal expansion and somatic mutation.

Authors:  M Shlomchik; M Mascelli; H Shan; M Z Radic; D Pisetsky; A Marshak-Rothstein; M Weigert
Journal:  J Exp Med       Date:  1990-01-01       Impact factor: 14.307

View more
  67 in total

1.  Severe, refractory type II essential mixed cryoglobulinemia treated with 2-chlorodeoxyadenosine and mycophenolate mofetil.

Authors:  Douglas E Gladstone; Marc G Golightly; Kenneth W Zamkoff
Journal:  Rheumatol Int       Date:  2005-02-10       Impact factor: 2.631

Review 2.  Haematology and neurology.

Authors:  Steven Austin; Hannah Cohen; Nick Losseff
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-04       Impact factor: 10.154

3.  Immunochemical composition of cryoglobulins generated in stroke.

Authors:  Levon Manukyan; Anna Boyajyan; Arsen Arakelyan; Violetta Ayvazyan; Elina Arakelova; Robert Sim; George Grigoryan
Journal:  J Clin Immunol       Date:  2008-11-04       Impact factor: 8.317

4.  Serum immunoglobulin free light chain levels in systemic autoimmune rheumatic diseases.

Authors:  F Gulli; C Napodano; M Marino; G Ciasca; K Pocino; V Basile; M Visentini; A Stefanile; L Todi; M De Spirito; G L Rapaccini; U Basile
Journal:  Clin Exp Immunol       Date:  2019-10-31       Impact factor: 4.330

Review 5.  Primary, post-primary and non-specific immunoglobulin M responses in HCV infection.

Authors:  Lynn B Dustin; Edgar D Charles
Journal:  Antivir Ther       Date:  2012-12-07

6.  Hepatitis C virus-host interactions: Etiopathogenesis and therapeutic strategies.

Authors:  Mohamed Hassan; Denis Selimovic; Abdelouahid El-Khattouti; Hanan Ghozlan; Youssef Haikel; Ola Abdelkader
Journal:  World J Exp Med       Date:  2012-04-20

7.  Pulmonary hemorrhage in cryoglobulinemia.

Authors:  Gordon Kirkpatrick; Tiffany Winstone; Pearce Wilcox; Stephan Van Eeden
Journal:  Can Respir J       Date:  2014-12-10       Impact factor: 2.409

Review 8.  Vasculitis: determinants of disease patterns.

Authors:  Gary S Hoffman; Leonard H Calabrese
Journal:  Nat Rev Rheumatol       Date:  2014-06-17       Impact factor: 20.543

9.  Clinicopathological features of cryoglobulinemic glomerulonephritis associated with HBV infection: a retrospective analysis of 8 cases in China.

Authors:  Chen Wang; Zi-Yin Ye; De-Hua Zeng; Fei-Lai Xie; Li-Juan Qu; Zhi-Yong Zheng
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

10.  Deletion of the fcgamma receptor IIb in thymic stromal lymphopoietin transgenic mice aggravates membranoproliferative glomerulonephritis.

Authors:  Anja S Mühlfeld; Stephan Segerer; Kelly Hudkins; Matthew D Carling; Min Wen; Andrew G Farr; Jeffrey V Ravetch; Charles E Alpers
Journal:  Am J Pathol       Date:  2003-09       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.